NASDAQ · AQST
Healthcare · Drug Manufacturers - Specialty & Generic
$4.55
Up+$0.11 (+2.48%)
Updated Oct 3, 2026, 2:03 AM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · AQST
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 2, 2026
AQST closed at $4.55 after 20 trading sessions, down 14.79% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 2, 2026 | $4.53 | $4.595 | $4.425 | $4.55 | 2.27M |
| Oct 1, 2026 | $4.60 | $4.61 | $4.435 | $4.44 | 2.69M |
| Sep 30, 2026 | $4.73 | $4.74 | $4.615 | $4.63 | 2.41M |
| Sep 29, 2026 | $4.70 | $4.75 | $4.55 | $4.67 | 1.71M |
| Sep 28, 2026 | $4.64 | $4.775 | $4.57 | $4.75 | 1.28M |
| Sep 25, 2026 | $4.82 | $4.86 | $4.66 | $4.68 | 1.91M |
| Sep 24, 2026 | $4.69 | $4.85 | $4.625 | $4.82 | 3.01M |
| Sep 23, 2026 | $4.92 | $5.005 | $4.70 | $4.70 | 1.95M |
| Sep 22, 2026 | $4.81 | $5.105 | $4.775 | $4.95 | 2.48M |
| Sep 21, 2026 | $4.65 | $4.825 | $4.56 | $4.78 | 2.46M |
| Sep 18, 2026 | $4.65 | $4.65 | $4.51 | $4.61 | 3.51M |
| Sep 17, 2026 | $5.00 | $5.00 | $4.615 | $4.66 | 2.53M |
| Sep 16, 2026 | $4.84 | $4.945 | $4.735 | $4.82 | 1.35M |
| Sep 15, 2026 | $4.82 | $4.90 | $4.76 | $4.81 | 1.61M |
| Sep 14, 2026 | $4.70 | $4.90 | $4.659 | $4.88 | 2.49M |
| Sep 11, 2026 | $4.99 | $5.1299 | $4.74 | $4.78 | 4.16M |
| Sep 10, 2026 | $5.13 | $5.30 | $4.915 | $4.99 | 3.28M |
| Sep 9, 2026 | $5.22 | $5.25 | $5.065 | $5.15 | 1.88M |
| Sep 8, 2026 | $5.39 | $5.4163 | $5.155 | $5.21 | 1.98M |
| Sep 4, 2026 | $5.32 | $5.485 | $5.29 | $5.34 | 2.12M |
The latest Smart Investors Daily articles mentioning AQST.
Company
Market Activity
Research & News
AQST research
Company profile and research snapshot.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 24, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 7, 2025 | Piper Sandler | Overweight | — |
| Oct 9, 2025 | JMP Securities | Market Outperform | — |
| Sep 8, 2025 | Oppenheimer | Outperform | — |
| Jun 17, 2025 | HC Wainwright & Co. | Buy | — |
Generated Oct 2, 2026, 9:05 PM
Aquestive Therapeutics gained 2.48% today as investors digest recent analyst commentary on the company's pipeline prospects. The modest rally reflects cautious optimism, though market sentiment suggests much of the upside from potential Anaphylam success may already be reflected in the current valuation.
Bottom line: AQST's modest gains today reflect stable sentiment around Anaphylam's prospects, though analyst commentary warns that much of the upside is already baked into valuations. Investors should monitor upcoming clinical data and regulatory developments closely, as execution will be critical to justifying current market expectations for this pipeline-dependent company.
SeekingAlpha · Sep 30, 2026
Aquestive Therapeutics offers a differentiated epinephrine product, Anaphylm, but faces pricing and market share headwinds. Learn why AQST stock is a hold.
Yahoo · Sep 29, 2026
Appoints Rich Daly, a life sciences executive with more than 30 years of leadership experience across large pharmaceutical companies, emerging biotechnology companies, and public company boards, to its Board of Directors WARREN, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, toda
Benzinga · Sep 17, 2026
Aquestive Therapeutics has resubmitted its New Drug Application to the FDA for Anaphylm, a sublingual film for severe allergic reactions.
Yahoo · Sep 17, 2026
Resubmission supported by positive topline human factors and pharmacokinetic (PK) study results announced in August 2026FDA will determine the resubmission classification and establish the applicable review timeline following its initial review of the resubmission WARREN, N.J., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innova
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AQST.
